| Shares Outstanding | 171,572,498 shares |
| Insider Shares | 30,783,097 shares |
| Insider Ownership | 17.94 % |
| Total Insiders | 19 |
Insider Sentiment Score
The Insider Sentiment Score finds the companies being bought by corporate insiders.
It is the result of a sophisticated, multi-factor quantitative model that identifies companies with the highest levels of insider accumulation. The scoring model uses a combination of the net number of insiders buying the prior 90 days, the total shares bought as a percentage of float, and the total shares owned by insiders. The number ranges from 0 to 100, with higher numbers indicating a higher level of accumulation to its peers, and 50 being the average.
Update Frequency: Daily
See Insiders Top Picks, which provides a list of companies with highest insider accumulation.
Officer Sentiment Score
The Officer Sentiment Score finds companies being bought by Corporate Officers.
By definition Corporate Officers are Corporate Insiders, but unlike some of the other Insiders (10% Shareholders and Board Members), Officers work for the company on a daily basis, and they user their own money when trading. (10% Shareholders and Board Members are often fund managers managing other people’s money.) As such, insider trades made by Officers are much more significant and should be treated appropriately.
Like the Insider Sentiment Score, the Officer Sentiment Score is the result of a sophisticated, multi-factor quantitative model that identifies companies with the highest levels of officer accumulation.
Update Frequency: Daily
See Insiders Top Picks, which provides a list of companies with highest insider sentiment.
Key Insider Metrics
This card shows how the company ranks along various insider metrics. The percentile rank shows how this company compares to other companies in the US markets. Higher rankings are indicative of better situations.
For example, it is generally accepted that insider buying is a positive indicator, so companies with more insider buying would rank higher than companies with less insider buying (or even insider selling).
Insider Trading Chart
Compass Therapeutics, Inc. insider trades are shown in the following chart. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on material, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Insider Roster and Profitability Metrics
This table shows the list known insiders, and is generated automatically from filings disclosed to the SEC. In addition to the names, most recent title, and director, officer, or 10% owner designation, we provide the latest disclosed holdings. Additionally, when possible we provide the historical trade performance for the insider. The historical trade performance is a weighted average of the performance of actual open-market purchase transactions made by the insider. For more information on how this is calculated, watch this YouTube webinar.
See our leaderboard of most profitable insider traders.
| Insider | Avg Profit (%) | Shares Owned |
Split Adjusted |
|---|---|---|---|
|
Errik Anderson
10% Owner -
|
5,673,912 | 5,673,912 | |
| Jonathan Anderman Gen Counsel & Corporate Sec - [O] | 21,000 | 21,000 | |
| Vered Bisker-Leib CHIEF EXECUTIVE OFFICER, Director - [D] [O] | 3,124,426 | 3,124,426 | |
| Ellen Chiniara Director - [D] | 0 | 0 | |
| Philip Ferneau Director - [D] | 400,280 | 400,280 | |
|
Carl L Gordon
Director, 10% Owner -
[D]
|
0 | 0 |
| Insider | Avg Profit (%) | Shares Owned |
Split Adjusted |
|---|---|---|---|
| Mary Ann Gray Director - [D] | 0 | 0 | |
| Ian Seth Jacobs President, Sec, CEO, & CFO, Director - [D] [O] | 500,000 | 500,000 | |
| Susan Kalled | 60,000 | ||
| Brett Kaplan | 30,000 | ||
| Neil Lerner CHIEF ACCOUNTING OFFICER - [O] | 320,000 | 320,000 | |
|
Orbimed Advisors Llc
Director, 10% Owner -
[D]
|
0 | 0 |
| Insider | Avg Profit (%) | Shares Owned |
Split Adjusted |
|---|---|---|---|
|
OrbiMed Genesis GP LLC
Director, 10% Owner -
[D]
|
18,389,422 | 0 | |
| Stephen P Squinto Director - [D] | 69,080 | 69,080 | |
| Schuetz Thomas J. CHIEF EXECUTIVE OFFICER, Director - [D] [O] | 6,480,825 | 6,480,825 | |
| Barry Shin CFO - [O] | 400,000 | 400,000 | |
| Julie Sunderland Director - [D] | 2,502,025 | 2,502,025 | |
| Miranda Jayne Toledano Director - [D] | 1,791,549 | 1,791,549 | |
|
Tompkins Mark N.
Director, 10% Owner -
[D]
|
9,500,000 | 9,500,000 |
Report errors via our new Insider Auditing Tool
Track Records of Insider Purchases - Short Term Profit Analysis
In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CMPX / Compass Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical .
The following table shows the most recent open market purchases that were not part of an automatic trading plan.
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Track Records of Insider Sales - Short Term Loss Analysis
In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CMPX / Compass Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical .
The following table shows the most recent open market sales that were not part of an automatic trading plan.
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Transaction History
Click the link icon to see the full transaction history. Transactions reported as part of a 10b5-1 automatic trading plan will have an X in the column marked 10b-5.
| File Date |
Trade Date |
Form | Insider | Ticker | Security Title | Code | Direct | Exercise Price |
Unit Price |
Units Changed |
Value Changed (1K) |
Remaining Options |
Remaining Shares |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-27 | 2025-05-27 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 2.1100 | 10,000 | 21 | 6,480,825 | ||||
| 2025-04-11 | 2025-04-09 | 4 | GORDON CARL L See footnotes | CMPX | Common Stock | I | 1.5900 | -3,571,428 | -5,679 | 0 | ||||
| 2025-04-11 | 2025-04-09 | 4 | ORBIMED ADVISORS LLC See footnotes | CMPX | Common Stock | I | 1.5900 | -3,571,428 | -5,679 | 0 | ||||
| 2025-04-08 | 2025-04-07 | 4 | Anderman Jonathan | CMPX | Common Stock | D | 1.5400 | 20,000 | 31 | 21,000 | ||||
| 2025-04-08 | 2025-04-07 | 4 | Lerner Neil | CMPX | Common Stock | D | 1.4200 | 20,000 | 28 | 320,000 | ||||
| 2025-02-11 | 2025-02-08 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 3.5000 | -41,687 | -146 | 6,470,825 | ||||
| 2025-01-13 | 2025-01-09 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 1.8600 | -58,054 | -108 | 6,512,512 | ||||
| 2024-12-10 | 2024-12-09 | 4 | Shin Barry | CMPX | Common Stock | D | 1.6500 | 400,000 | 660 | 400,000 | ||||
| 2024-12-10 | 3 | Lerner Neil | CMPX | Common Stock | D | 300,000 | ||||||||
| 2024-08-09 | 3 | Anderman Jonathan | CMPX | Common Stock | D | 1,000 | ||||||||
| 2024-02-09 | 2024-02-08 | 4 | Bisker-Leib Vered | CMPX | Common Stock | D | 1.4500 | -49,198 | -71 | 3,124,426 | ||||
| 2024-02-09 | 2024-02-08 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 1.4500 | -44,782 | -65 | 6,570,566 | ||||
| 2024-01-10 | 2024-01-09 | 4 | Bisker-Leib Vered | CMPX | Common Stock | D | 1.9300 | 1,753,125 | 3,384 | 3,173,624 | ||||
| 2024-01-10 | 2024-01-09 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 1.9300 | 637,500 | 1,230 | 6,615,348 | ||||
| 2023-11-21 | 2023-11-17 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 1.5000 | -44,025 | -66 | 5,977,848 | ||||
| 2023-11-21 | 2023-11-17 | 4 | Bisker-Leib Vered | CMPX | Common Stock | D | 1.5000 | -64,415 | -97 | 1,420,499 | ||||
| 2023-03-10 | 2023-03-10 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 3.3700 | 10,000 | 34 | 6,021,873 | ||||
| 2023-02-27 | 2023-02-27 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 3.9800 | 20,000 | 80 | 6,011,873 | ||||
| 2023-02-15 | 2023-02-15 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 3.8600 | 20,000 | 77 | 5,991,873 | ||||
| 2023-02-09 | 2023-02-08 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 500,000 | 5,971,873 | ||||||
| 2023-02-09 | 2023-02-08 | 4 | Bisker-Leib Vered | CMPX | Common Stock | D | 400,000 | 1,484,914 | ||||||
| 2023-01-31 | 2023-01-31 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 4.0500 | 20,000 | 81 | 5,471,873 | ||||
| 2023-01-24 | 2023-01-24 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 4.1900 | 20,000 | 84 | 5,451,873 | ||||
| 2022-11-25 | 2022-11-25 | 4 | Bisker-Leib Vered | CMPX | Common Stock | D | 4.3600 | -2 | -0 | 1,060,414 | ||||
| 2022-11-25 | 2022-11-23 | 4 | Bisker-Leib Vered | CMPX | Common Stock | D | 4.3000 | -9,569 | -41 | 1,060,416 | ||||
| 2022-11-25 | 2022-11-22 | 4 | Bisker-Leib Vered | CMPX | Common Stock | D | 4.1900 | -14,929 | -63 | 1,069,985 | ||||
| 2022-11-22 | 2022-11-21 | 4 | Bisker-Leib Vered | CMPX | Common Stock | D | 4.3400 | -16,035 | -70 | 1,084,914 | ||||
| 2022-11-22 | 2022-11-18 | 4 | Bisker-Leib Vered | CMPX | Common Stock | D | 4.4000 | -6,226 | -27 | 1,107,175 | ||||
| 2022-11-10 | 2022-11-08 | 4 | ORBIMED ADVISORS LLC See Footnotes | CMPX | Common Stock | I | 3.2100 | 402,000 | 1,290 | 15,219,994 | ||||
| 2022-11-10 | 2022-11-08 | 4 | GORDON CARL L See Footnotes | CMPX | Common Stock | I | 3.2100 | 402,000 | 1,290 | 15,219,994 | ||||
| 2022-09-28 | 2022-09-28 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 2.3200 | 10,000 | 23 | 5,431,873 | ||||
| 2022-09-27 | 2022-09-26 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 2.2700 | 15,000 | 34 | 5,421,873 | ||||
| 2022-09-08 | 2022-09-07 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 3.0300 | 15,000 | 45 | 5,406,873 | ||||
| 2022-09-01 | 2022-09-01 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 2.8300 | 15,000 | 42 | 5,391,873 | ||||
| 2022-08-17 | 2022-08-17 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 3.0500 | 15,000 | 46 | 5,376,873 | ||||
| 2022-08-10 | 2022-08-10 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 2.6400 | 15,000 | 40 | 5,361,873 | ||||
| 2022-08-02 | 2022-08-01 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 2.5800 | 15,000 | 39 | 5,346,873 | ||||
| 2022-06-21 | 2022-06-21 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 2.8000 | 20,000 | 56 | 5,331,873 | ||||
| 2022-06-17 | 2022-06-16 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 2.3400 | 20,000 | 47 | 5,311,873 | ||||
| 2022-06-13 | 2022-06-13 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 2.2900 | 30,000 | 69 | 5,291,873 | ||||
| 2022-06-07 | 2022-06-06 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 2.8300 | 30,000 | 85 | 5,261,873 | ||||
| 2022-06-01 | 2022-06-01 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 3.0300 | 20,000 | 61 | 5,231,873 | ||||
| 2022-05-26 | 2022-05-26 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 3.0400 | 20,000 | 61 | 5,211,873 | ||||
| 2022-05-24 | 2022-05-23 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 2.7200 | 18,355 | 50 | 5,191,873 | ||||
| 2022-05-17 | 2022-05-17 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 2.4700 | 20,215 | 50 | 5,173,518 | ||||
| 2022-05-13 | 2022-05-13 | 4 | GORDON CARL L See Footnotes | CMPX | Common Stock | I | 2.4900 | 30,722 | 76 | 14,817,994 | ||||
| 2022-05-13 | 2022-05-12 | 4 | GORDON CARL L See Footnotes | CMPX | Common Stock | I | 2.3500 | 97,094 | 228 | 14,787,272 | ||||
| 2022-05-13 | 2022-05-11 | 4 | GORDON CARL L See Footnotes | CMPX | Common Stock | I | 1.7900 | 64,700 | 116 | 14,690,178 | ||||
| 2022-05-13 | 2022-05-13 | 4 | ORBIMED ADVISORS LLC See Footnotes | CMPX | Common Stock | I | 2.4900 | 30,722 | 76 | 14,817,994 | ||||
| 2022-05-13 | 2022-05-12 | 4 | ORBIMED ADVISORS LLC See Footnotes | CMPX | Common Stock | I | 2.3500 | 97,094 | 228 | 14,787,272 | ||||
| 2022-05-13 | 2022-05-11 | 4 | ORBIMED ADVISORS LLC See Footnotes | CMPX | Common Stock | I | 1.7900 | 64,700 | 116 | 14,690,178 | ||||
| 2022-05-10 | 2022-05-10 | 4 | Schuetz Thomas J. | CMPX | Common Stock | D | 1.8000 | 27,836 | 50 | 5,153,303 | ||||
| 2022-05-10 | 2022-05-10 | 4 | GORDON CARL L See Footnotes | CMPX | Common Stock | I | 1.6000 | 24,447 | 39 | 14,625,478 | ||||
| 2022-05-10 | 2022-05-09 | 4 | GORDON CARL L See Footnotes | CMPX | Common Stock | I | 1.5600 | 90,712 | 142 | 14,601,031 | ||||
| 2022-05-10 | 2022-05-06 | 4 | GORDON CARL L See Footnotes | CMPX | Common Stock | I | 1.6300 | 10,200 | 17 | 14,510,319 | ||||
| 2022-05-10 | 2022-05-10 | 4 | ORBIMED ADVISORS LLC See Footnotes | CMPX | Common Stock | I | 1.6000 | 24,447 | 39 | 14,625,478 | ||||
| 2022-05-10 | 2022-05-09 | 4 | ORBIMED ADVISORS LLC See Footnotes | CMPX | Common Stock | I | 1.5600 | 90,712 | 142 | 14,601,031 | ||||
| 2022-05-10 | 2022-05-06 | 4 | ORBIMED ADVISORS LLC See Footnotes | CMPX | Common Stock | I | 1.6300 | 10,200 | 17 | 14,510,319 | ||||
| 2022-04-28 | 2022-04-26 | 4 | Chiniara Ellen | CMPX | Stock Option (Right to Buy) | D | 1.51 | 45,000 | 45,000 | |||||
| 2022-04-28 | 3 | GRAY MARY ANN | CMPX | Common Stock, $.0001 Par Value | D | 0 | ||||||||
| 2022-04-28 | 2022-04-26 | 4 | GRAY MARY ANN | CMPX | Stock Option (Right to Buy) | D | 1.51 | 45,000 | 45,000 | |||||
| 2022-04-28 | 3 | Chiniara Ellen | CMPX | Common Stock, $.0001 Par Value | D | 0 | ||||||||
| 2022-02-23 | 2022-02-18 | 4 | SQUINTO STEPHEN P | CMPX | Stock Option (Right to Buy) | D | 2.40 | 30,000 | 30,000 | |||||
| 2022-02-23 | 2022-02-18 | 4 | GORDON CARL L | CMPX | Stock Option (Right to Buy) | D | 2.40 | 30,000 | 30,000 | |||||
| 2022-02-23 | 2022-02-18 | 4 | Ferneau Philip | CMPX | Stock Option (Right to Buy) | D | 2.40 | 30,000 | 30,000 | |||||
| 2022-02-23 | 2022-02-18 | 4 | Kaplan Brett | CMPX | Stock Option (Right to Buy) | D | 2.40 | 30,000 | 30,000 | |||||
| 2022-02-23 | 2022-02-18 | 4/A | Bisker-Leib Vered | CMPX | Stock Option (Right to Buy) | D | 2.40 | 500,000 | 500,000 | |||||
| 2022-02-23 | 2022-02-18 | 4/A | Schuetz Thomas J. | CMPX | Stock Option (Right to Buy) | D | 2.40 | 700,000 | 700,000 | |||||
| 2022-02-23 | 2022-02-18 | 4/A | Kalled Susan | CMPX | Stock Option (Right to Buy) | D | 2.40 | 60,000 | 60,000 | |||||
| 2022-02-18 | 2022-02-17 | 4 | Schuetz Thomas J. | CMPX | Stock Option (Right to Buy) | D | 2.52 | 700,000 | 700,000 | |||||
| 2022-02-18 | 2022-02-17 | 4 | Bisker-Leib Vered | CMPX | Stock Option (Right to Buy) | D | 2.52 | 500,000 | 500,000 | |||||
| 2022-02-18 | 2022-02-17 | 4 | Kalled Susan | CMPX | Stock Option (Right to Buy) | D | 2.52 | 60,000 | 60,000 | |||||
| 2021-11-18 | 2021-11-16 | 4 | Bisker-Leib Vered | CMPX | Common Stock | D | 600,000 | 1,113,401 | ||||||
| 2021-11-18 | 2021-11-16 | 4 | Schuetz Thomas J. | NONE | Common Stock | D | 600,000 | 5,125,467 | ||||||
| 2021-11-08 | 2021-11-04 | 4 | GORDON CARL L See Footnotes | CMPX | Common Stock | I | 3.5000 | 3,571,428 | 12,500 | 3,571,428 | ||||
| 2021-11-08 | 2021-11-04 | 4 | GORDON CARL L See Footnotes | CMPX | Common Stock | I | 3.5000 | 1,785,715 | 6,250 | 14,500,119 | ||||
| 2021-11-08 | 2021-11-04 | 4 | ORBIMED ADVISORS LLC See Footnotes | CMPX | Common Stock | I | 3.5000 | 3,571,428 | 12,500 | 3,571,428 | ||||
| 2021-11-08 | 2021-11-04 | 4 | ORBIMED ADVISORS LLC See Footnotes | CMPX | Common Stock | I | 3.5000 | 1,785,715 | 6,250 | 14,500,119 | ||||
| 2021-06-29 | 2021-06-25 | 4 | Toledano Miranda Jayne | CMPX | Stock Option (Right to Buy) | D | 4.90 | 50,000 | 50,000 | |||||
| 2021-06-29 | 2021-06-25 | 4 | Toledano Miranda Jayne | CMPX | Common Stock, $.0001 Par Value | D | 1,791,549 | 1,791,549 | ||||||
| 2021-06-29 | 3 | Toledano Miranda Jayne | CMPX | Common Stock, $.0001 Par Value | D | 0 | ||||||||
| 2021-05-05 | 2021-05-03 | 4 | Kalled Susan | NONE | Stock Option (Right to Buy) | D | 7.00 | 260,000 | 260,000 | |||||
| 2021-03-01 | 2021-02-09 | 4 | Schuetz Thomas J. | CMPX | Stock Option (Right to Buy) | D | 5.00 | 700,000 | 700,000 | |||||
| 2021-03-01 | 2021-02-09 | 4 | Bisker-Leib Vered | CMPX | Stock Option (Right to Buy) | D | 5.00 | 400,000 | 400,000 | |||||
| 2020-12-23 | 2020-12-22 | 4 | Schuetz Thomas J. | CMPX | Stock Option (Right to Buy) | D | 5.00 | 250,000 | 250,000 | |||||
| 2020-09-14 | 2020-09-10 | 4 | Kaplan Brett | NONE | Stock Option (Right to Buy) | D | 5.00 | 60,000 | 60,000 | |||||
| 2020-08-10 | 2020-08-06 | 4 | SQUINTO STEPHEN P | NONE | Stock Option (Right to Buy) | D | 5.00 | 30,000 | 30,000 | |||||
| 2020-08-10 | 2020-08-06 | 4 | Bisker-Leib Vered | NONE | Stock Option (Right to Buy) | D | 5.00 | 600,000 | 600,000 | |||||
| 2020-08-10 | 2020-08-06 | 4 | Schuetz Thomas J. | NONE | Stock Option (Right to Buy) | D | 5.00 | 500,000 | 500,000 | |||||
| 2020-06-29 | 3 | ANDERSON ERRIK | NONE | Common Stock | D | 8,534,999 | ||||||||
| 2020-06-29 | 3 | ANDERSON ERRIK See footnote (1) | NONE | Common Stock | I | 6,952,169 | ||||||||
| 2020-06-29 | 3 | ANDERSON ERRIK See footnote (2) | NONE | Common Stock | I | 5,673,912 | ||||||||
| 2020-06-23 | 3 | Sunderland Julie | NONE | Common Stock | I | 4,425,814 | ||||||||
| 2020-06-23 | 3 | Sunderland Julie | NONE | Common Stock | I | 4,425,814 | ||||||||
| 2020-06-23 | 3 | Sunderland Julie | NONE | Common Stock | I | 4,425,814 | ||||||||
| 2020-06-23 | 3 | Ferneau Philip | NONE | Common Stock | I | 4,720,100 | ||||||||
| 2020-06-23 | 3 | Ferneau Philip | NONE | Common Stock | I | 4,720,100 | ||||||||
| 2020-06-23 | 3 | Ferneau Philip | NONE | Common Stock | I | 2,585,470 | ||||||||
| 2020-06-23 | 3 | Ferneau Philip | NONE | Common Stock | I | 4,720,100 | ||||||||
| 2020-06-23 | 3 | Ferneau Philip | NONE | Common Stock | I | 2,585,470 | ||||||||
| 2020-06-23 | 3 | Ferneau Philip | NONE | Common Stock | I | 2,585,470 | ||||||||
| 2020-06-23 | 3 | Schuetz Thomas J. | NONE | Common Stock | D | 8,856,072 | ||||||||
| 2020-06-23 | 3 | Schuetz Thomas J. | NONE | Common Stock | D | 8,856,072 | ||||||||
| 2020-06-23 | 3 | Schuetz Thomas J. | NONE | Common Stock | D | 8,856,072 | ||||||||
| 2020-06-23 | 3 | Bisker-Leib Vered | NONE | Common Stock | D | 1,026,802 | ||||||||
| 2020-06-23 | 3 | Bisker-Leib Vered | NONE | Common Stock | D | 1,026,802 | ||||||||
| 2020-06-23 | 3 | Bisker-Leib Vered | NONE | Common Stock | D | 1,026,802 | ||||||||
| 2020-06-23 | 2020-06-19 | 4 | ORBIMED ADVISORS LLC | NONE | Common Stock | D | 5.0000 | 1,455,132 | 7,276 | 12,714,404 | ||||
| 2020-06-23 | 2020-06-19 | 4 | GORDON CARL L | NONE | Common Stock | I | 5.0000 | 1,455,132 | 7,276 | 12,714,404 | ||||
| 2020-06-23 | 2020-06-19 | 4 | Ferneau Philip | NONE | Common Stock | I | 5.0000 | 250,000 | 1,250 | 400,280 | ||||
| 2020-06-23 | 2020-06-19 | 4 | Ferneau Philip | NONE | Common Stock | I | 5.0000 | 64,066 | 320 | 2,348,976 | ||||
| 2020-06-23 | 2020-06-19 | 4 | Schuetz Thomas J. | NONE | Common Stock | D | 5.0000 | 97,431 | 487 | 4,525,467 | ||||
| 2020-06-23 | 2020-06-19 | 4 | Sunderland Julie | NONE | Common Stock | I | 5.0000 | 289,118 | 1,446 | 2,502,025 | ||||
| 2020-06-23 | 3 | GORDON CARL L | NONE | Common Stock | I | 22,518,544 | ||||||||
| 2020-06-23 | 3 | GORDON CARL L | NONE | Common Stock | I | 22,518,544 | ||||||||
| 2020-06-23 | 3 | GORDON CARL L | NONE | Common Stock | I | 22,518,544 | ||||||||
| 2020-06-23 | 3 | OrbiMed Capital GP V LLC | NONE | Common Stock | D | 22,518,544 | ||||||||
| 2020-06-23 | 3 | OrbiMed Capital GP V LLC | NONE | Common Stock | D | 22,518,544 | ||||||||
| 2020-06-23 | 3 | OrbiMed Capital GP V LLC | NONE | Common Stock | D | 22,518,544 | ||||||||
| 2020-06-23 | 3 | OrbiMed Capital GP V LLC | NONE | Common Stock | D | 22,518,544 | ||||||||
| 2020-06-23 | 3 | SQUINTO STEPHEN P | NONE | Common Stock | D | 69,080 | ||||||||
| 2020-06-23 | 3 | SQUINTO STEPHEN P | NONE | Common Stock | D | 69,080 | ||||||||
| 2020-06-23 | 3 | SQUINTO STEPHEN P | NONE | Common Stock | D | 69,080 | ||||||||
| 2018-07-30 | 3 | Jacobs Ian Seth | NONE | Common Stock, par value $0.0001 | D | 500,000 | ||||||||
| 2018-07-30 | 3 | Jacobs Ian Seth | NONE | Common Stock, par value $0.0001 | D | 500,000 | ||||||||
| 2018-07-30 | 3 | Jacobs Ian Seth | NONE | Common Stock, par value $0.0001 | D | 500,000 | ||||||||
| 2018-07-30 | 3 | Tompkins Mark N. | NONE | Common Stock, par value $0.0001 | D | 9,500,000 | ||||||||
| 2018-07-30 | 3 | Tompkins Mark N. | NONE | Common Stock, par value $0.0001 | D | 9,500,000 | ||||||||
| 2018-07-30 | 3 | Tompkins Mark N. | NONE | Common Stock, par value $0.0001 | D | 9,500,000 |
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)
